Bristol-Myers Squibb Company Financial Analysis
Current Price: $54.72 +0.48%
Market Cap: $111.74B
Sector: Healthcare
P/E Ratio: 15.61
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi
Report Contents
- Income Statement Analysis (5-year history)
- Balance Sheet Overview
- Cash Flow Statement
- Key Financial Ratios
- Valuation Metrics (P/E, EV/EBITDA, P/S)
- Peer Comparison
- Revenue & Earnings Growth Trends
- Margin Analysis
- Analyst Price Targets
- DCF Valuation Model